Abstract

AN OVERVIEW OF ANEMIA IN CHRONIC KIDNEY DISEASE PATIENTS

Kuchibhatla Lakshmi Vardhani*, Anjana Sri Satya Veravali, Amrutha Jampana, Beg Karishma, Natta Prathibha and Kantamaneni Padmalatha

.

Abstract

Anemia is a known side effect of chronic renal disease, yet it is still challenging to treat. The benefits of erythropoiesis-stimulating drugs (ESAs) seem to be limited to reducing the need for blood transfusions and possibly improving quality of life. Hemoglobin levels are increased by ESAs. Prolyl hydroxylase inhibitor of hypoxia-inducible factor (HIF-PHI), Prolyl hydroxylase inhibitors (PHIs) which increase endogenous erythropoietin production, have recently been developed and show promise for improving outcomes for those with anemia brought on by the chronic renal illness. These drugs are used internationally and have been found in randomized controlled trials to be at least as effective as ESAs.On the other hand, recent clinical trials have clarified significant iron supplementation features, which may alter future treatment aims. Oral iron supplementation is the preferred form of treatment because of its ease of use and cost-effectiveness. In severe cases, ESA therapy is preferred because it provides rapid relief of the symptoms of anemia and reduces the number of transfusions required.

Keywords: Anemia, chronic kidney disease, Erythropoiesis stimulating agents, Prolyl hydroxylase inhibitor, iron, blood transfusion.